Edesa Story

<div class='circular--portrait' style='background:#FF6600;color: #FFFAFA;font-size:4em;'>EB</div>
EDSA -- USA Stock  

USD 4.84  0.83  14.64%

Despite somewhat weak basic indicators, Edesa Biotech sustained solid returns over the last few months and may actually be approaching a breakup point. Edesa Biotech probability of financial unrest is under 45 percent. Will Edesa Biotech investors continue to buy in October?
Published over three months ago
View all stories for Edesa Biotech | View All Stories
Does Edesa Biotech (NASDAQ:EDSA) have strong basic indicators based on the current rise?
Edesa Biotech is very risky given 1 month investment horizon. Edesa Biotech secures Sharpe Ratio (or Efficiency) of 0.15, which denotes the company had 0.15% of return per unit of risk over the last month. Our standpoint towards predicting the volatility of a stock is to use Edesa Biotech market data together with company specific technical indicators. We were able to analyze twenty-eight different technical indicators, which can help you to evaluate if expected returns of 2.7% are justified by taking the suggested risk. Use Edesa Biotech Downside Deviation of 7.32, mean deviation of 8.81, and Coefficient Of Variation of 664.46 to evaluate company specific risk that cannot be diversified away.
Typically, a company's financial statements are the reports that show the financial position of the company. There are three main documents that fall into the category of financial statements. These documents include Edesa Biotech income statement, its balance sheet, and the statement of cash flows. Potential Edesa Biotech investors and stakeholders use financial statements to determine how well the company is positioned to perform in the future. Although Edesa Biotech investors may use each financial statement separately, they are all related. The changes in Edesa Biotech's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Edesa Biotech's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages. The goal of Edesa Biotech fundamental analysis is to do accurate financial forecasts. There are several possible objectives to fundamental analysis, such as projecting of Edesa Biotech performance into the future periods or doing a reasonable stock valuation. The intrinsic value of Edesa Biotech shares is the value that is considered the true value of the share. If the intrinsic value Edesa is higher than its market price, buying is generally recommended. If it is equal to the market price, it is recommended to hold; and if it is less than the market price, then one should sell all shares Edesa Biotech. Please read more on our fundamental analysis page.

Are Edesa Biotech Earnings Expected to grow?

The future earnings power of Edesa Biotech involves the interaction of many company-specific, industry, and economic forces. Earnings estimates embody investors' opinions of Edesa Biotech factors such as sales growth, product demand, competitive industry environment, profit margins, and cost controls. Edesa Biotech stock prices adjust as these expectations change or are proven wrong. The main thing to remember is that equities with high expected earnings growth tend to underperform the market because it is usually difficult to meet the market's high expectations. Companies with low earnings expectations tend to do better than expected. Please use our latest analysis of Edesa expected earnings.

How Edesa utilizes its cash?

To perform a cash flow analysis of Edesa Biotech, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash Edesa Biotech is receiving and how much cash it distributes out in a given period. The Edesa Biotech cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities. Edesa Biotech Net Cash Flow from Operations is projected to increase significantly based on the last few years of reporting. The past year's Net Cash Flow from Operations was at (1.29 Million)

Edesa Biotech Gross Profit

Edesa Biotech Gross Profit growth is one of the most critical measures in evaluating the company. The Gross Profit growth rate is calculated simply by comparing Edesa Biotech previous period's values with its current period's values. Each time period you're measuring should be of equal lengths the increase or decrease, in a company's Gross Profit between two periods. Here we show Edesa Biotech Gross Profit growth over the last 10 years. Please check Gross Profit in more details.

Exercise of in-the-money or at-the-money derivative position by Pay Paul William of 1218 shares of Edesa Biotech

Legal trades by Edesa Biotech insiders are very common, as founders, directors, or employees of any publicly traded firm often have stock or stock options. These trades are made public in the United States through the filing of Form 4 of the Securities and Exchange Commission. Below entry was recorded recently and is publicly available as an insider trade:
Edesa insider trading alert for exercise of common share warrants (right to buy) by Pay Paul William, the corporate stakeholder, on 10th of November 2020. This event was filed by Edesa Biotech Inc with SEC on 2020-11-10. Statement of changes in beneficial ownership - SEC Form 4 [view details]   
Note, although insider trading is legal, in the United States, Canada, Australia, and Germany, for mandatory reporting purposes, corporate insiders are defined as a company's officers, directors, and any beneficial owners of more than 10% of a class of the company's equity securities.

Breaking down Edesa Biotech Indicators

Although in the United States, the Securities and Exchange Commission has enforced strong rules to prevent insiders from engaging in insider trading, finding insiders among active shareholders of Edesa Biotech is not uncomon. Institutional investor usually refers to an organization that invests money in Edesa Biotech on behalf of clients or other money managers. Buying and selling of large positions of Edesa Biotech stock by institutional investors can create supply and demand imbalances that result in sudden price moves of Edesa Biotech stock. Let's take a look at how the ownership of Edesa is distributed among investors.

Ownership Allocation

Edesa Biotech retains a total of 9.41 Million outstanding shares. Edesa Biotech retains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company outstanding shares. Since such a large part of the company is owned by insiders, it is advisable to analyze if each of these insiders have been buying or selling the stock in recent months. Remember, it does not matter who owns the company or if the company is currently losing money. If the true value of the company is more than the market pays for it currently, you can still have a good investment opportunity.

Retail Investors
Retail Investors28.34

Asset Utilization

The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Edesa Biotech has an asset utilization ratio of 11.46 percent. This suggests that the company is making $0.11 for each dollar of assets. An increasing asset utilization means that Edesa Biotech is more efficient with each dollar of assets it utilizes for everyday operations.

Current Assets
5.8 M
Current Assets5.82 Million97.93
Assets Non Current6,822.330.11

Will Edesa Biotech growth be real after the rise?

The treynor ratio is down to 2.05 as of today. Edesa Biotech is displaying above-average volatility over the selected time horizon. Investors should scrutinize Edesa Biotech independently to ensure intended market timing strategies are aligned with expectations about Edesa Biotech volatility.

Our Bottom Line On Edesa Biotech

Whereas few other entities within the biotechnology industry are still a little expensive, even after the recent corrections, Edesa Biotech may offer a potential longer-term growth to investors. With a somewhat neutral outlook on your 30 days horizon, it may be better to hold off any trading activity and neither trade new shares of Edesa nor drop your existing holdings in the Stock. It seems the expected volatility has not yet been fully factored into the current price. Please use our equity advice module to run different scenarios to ensure your current risk level and investment horizon are fully reflective of your current investing preferences in regards to Edesa Biotech.

About Contributor

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Vlad Skutelnik do not own shares of Edesa Biotech. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com